Neurology

The new drug safinamide might have some impact in preventing the involuntary movements characteristic of Parkinson's disease. However, it did not perform any better than placebo over a two-year period.

New treatment is effective in Canada and U.S., but not in rest of North America; epilepsy classification may have been a factor

Real-world outcomes with investigational drug still favourable

With the help of several physicians we've narrowed the list to nine apps that doctors may deem both beneficial to their practice and which can be accessed via multiple platforms.

NIH puts an early end to its trial of combination cholesterol therapy

Certain drugs can adversely affect the skeleton and increase the risk of osteoporosis or fractures.

Byetta: second GLP-1 agonist for diabetes; Gilenya: first oral disease-modifying drug for MS; Nucynta CR: new opioid for moderate—moderate/severe pain.